Impact of environmental factors on spontaneous reporting trends and safety signal detection in the EudraVigilance database

Changes brought to the ecosystem and geopolitical environment can have an effect on several fields including the healthcare system. Recently, we observed the impact that COVID-19 pandemic has had on the healthcare workers’ practices and people’s behaviour regarding their health status. Changes in spontaneous reporting trends were also observed. Lately, Europe has also witnessed the Brexit which is another important event that can influence spontaneous reporting practices knowing that the United Kingdom is an important source of spontaneous reports.

Artificial intelligence-powered approach for strategic pharmaceutical portfolio management based on a priori estimation of clinical trial success evolution

Drug development process is time consuming, expensive, complex and highly risky. The nature of risk in this industry is multidimensional. One important dimension involves clinical development since late-stage development failures are the costliest. If pharmacological efficacy and safety remain well-known failure factors, the literature abounds on a multitude of important failure risk factors of a strategic, operational and commercial nature. In addition to being difficult for humans to control, the decisions associated with these risk factors are major contributors to failure in late stages.

ATF3+ tumor-innervating neurons control anti-cancer immunity

Itch is a common feature of various cancers, while cancer cells actively secrete factors promoting neuronal infiltration of tumors. Experimentally stopping the electrical signals of tumor infiltrating neurons helps decrease tumor growth, but the specific means by which neurons regulate cancer cells survival is yet to be uncovered.

Modulation of proteinase receptor 2: a novel target for cancer immunotherapy

Treatments empowering patient’s own immune system (immunotherapy) have revolutionized cancer treatment this last decade, showing substantial clinical activity in different tumor types. However, 60% of cancer patients still fail to respond to immunotherapy and other standard of care. Our laboratory recently identified the proteinase receptor 2as a new target to overcome immunotherapy resistance. We propose to investigate the therapeutic potential of this receptor for cancer immunotherapy.

Pharmacokinetics of nicotine delivered by a novel electronic nicotine delivery system in healthy adult smokers: a feasibility study

Ditch Labs is a medical technology company developing a new treatment for smoking cessation. The objective of this research project is to understand how nicotine delivered by a novel electronic nicotine deliver system travels through the body from its absorption to its excretion. The study is important because it will allow Ditch Labs to select optimal nicotine doses to be delivered to patients and then subsequently reduced over a period of several weeks until complete cessation.

Développement de nouvelles molécules bioactives et d’acides aminés biosourcés par dérivatisation de triterpènes naturels

Les végétaux demeurent de nos jours une source incontournable de molécules bioactives pour le développement d'agents thérapeutiques novateurs. Par contre, l'étude et l'utilisation des molécules d'origine végétale sont souvent limitées par leur manque de solubilité dans l'eau et leur faible biodisponibilité. Pour surmonter ces limitations, l'ajout de groupements polaires sur les molécules appelé dérivatisation est une approche attrayante pour améliorer les propriétés physico-chimiques et pharmacologiques des produits naturels.

Évaluation des initiatives favorisant l’utilisation optimale des médicaments biosimilaires dans le secteur des payeurs privés

iA Groupe financier est un groupement de sociétés d’assurance et de gestion de patrimoine des plus importants au Canada. Plus de la moitié des personnes couvertes par iA viennent du Québec. Le 6 juillet 2021, Régie d’assurance maladie du Québec (RAMQ) a annoncé une transition des patients utilisant des médicaments biologiques de référence, c’est-à-dire des médicaments fabriqués à partir d’organismes vivants ou de cellules, vers des médicaments biologiques similaires.

Pharmacological optimization of OpKemoTM, a silica-based nanoparticle platform for oncology

Pharma in silica is a preclinical stage company developing silica-based nanoparticles to formulate more efficient and better tolerated chemotherapy modalities. In this collaboration, they will benefit from the expertise of the laboratories of Prof N. Bertrand and S. Fortin to obtain useful chemistry, manufacturing, and control (CMC) information and advance their nanoparticles toward regulatory approval.

Méthode de validation in silico d’une prothèse d’épaule innovante pour maximiser la mobilité des patients

Actuellement les prothèses d’épaules dites inversées sont préconisées dans le cas de coiffe des rotateurs endommagée. Ces prothèses assurent la stabilité de l’articulation mais limitent la mobilité articulaire, notamment en élévation du bras. Pour pallier cette déficience, Statera Medical propose un design de prothèse innovant avec un degré de liberté additionnel. En collaboration avec le laboratoire de simulation et modélisation du mouvement, cette nouvelle prothèse sera testée puis optimisée par des simulations musculosquelettiques.

Inflammation, RNA stability, therapeutics

Different autoimmune diseases often have similar mechanisms that trigger and drive the pathology. Therefore, it’s logical that having one autoimmune disorder increases the risk of acquiring another one. At the same time, autoimmune disease cooccurrence is rare. Our research found that type 1 diabetes (T1D) and multiple sclerosis (MS) share common mechanisms. We pinpointed the protein, called NLRX1, that protects against both autoimmune diseases. This protein belongs to the class of pattern recognition receptors that we use to detect pathogens.